| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/21/2004 | EP1439164A1 Novel phenylethanolamine compounds having beta2-acceptor excitatory function and their preparation method |
| 07/21/2004 | EP1438973A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists |
| 07/21/2004 | EP1438972A1 Remedy for ischemic heart failure |
| 07/21/2004 | EP1438971A1 Immunopotentiators in thermotherapy for cancer |
| 07/21/2004 | EP1438965A1 Use of extracts from Hoodia gordonii and Hoodia lugardii for the preparation of a medicament for use in the suppression of appetite |
| 07/21/2004 | EP1438964A1 Process for producing collagen production enhancers and use thereof |
| 07/21/2004 | EP1438962A1 DRUGS COMPRISING COMBINATION OF TRIAZASPIRO 5,5 U NDECANE DERIVATIVE WITH CYTOCHROME P450 ISOZYME 3A4 INHIBITOR AND/OR P−GLYCOPROTEIN INHIBITOR |
| 07/21/2004 | EP1438961A1 Bioequivalent composition of itraconazole dispersed in a hydrophilic polymer |
| 07/21/2004 | EP1438960A1 Compostion of itraconazole dispersed in a hydrophilic polymer having enhanced bioavailability |
| 07/21/2004 | EP1438959A1 Controlled release oxycodone compositions |
| 07/21/2004 | EP1438958A1 Carbamate substituted imidazoquinolines |
| 07/21/2004 | EP1438957A1 Benzothiophene formulations of a specific dosage |
| 07/21/2004 | EP1438956A1 Alpha-aminoamide derivatives useful as antimigraine agents |
| 07/21/2004 | EP1438955A1 High dose liposomal aerosol formulations |
| 07/21/2004 | EP1438900A1 Use of soy formulations in food compositions |
| 07/21/2004 | EP1438898A2 Method for maintaining an existing level of body fat and/or body weight |
| 07/21/2004 | EP1438434A2 Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof |
| 07/21/2004 | EP1438418A2 Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| 07/21/2004 | EP1438415A2 Method for preparing heparin from mast cell cultures |
| 07/21/2004 | EP1438409A1 Use of a double strand ribonucleic acid for treating an infection with a positive-strand rna-virus |
| 07/21/2004 | EP1438406A1 Drug for treating a carcinoma of the pancreas |
| 07/21/2004 | EP1438405A1 Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene |
| 07/21/2004 | EP1438404A2 Inhibition of specific histone deacetylase isoforms |
| 07/21/2004 | EP1438402A2 Modulators of bone homeostasis identified in a high-throughput screen |
| 07/21/2004 | EP1438389A2 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer |
| 07/21/2004 | EP1438386A2 Transmembrane protein differentially expressed in cancer |
| 07/21/2004 | EP1438379A1 Decontamination of surfaces contaminated with prion-infected material with oxidizing agent-based formulations |
| 07/21/2004 | EP1438378A1 Cholesterol lowering structured lipids with omega 6 pufa |
| 07/21/2004 | EP1438377A1 Cholesterol lowering structured lipids with omega 3 pufa |
| 07/21/2004 | EP1438338A2 Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof |
| 07/21/2004 | EP1438321A1 Modified l-nucleic acid |
| 07/21/2004 | EP1438320A1 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same |
| 07/21/2004 | EP1438319A1 Derivatives of etoposide and analogs, and pharmaceutical compositions containing them |
| 07/21/2004 | EP1438316A1 Phosphonic acid compounds as inhibitors of serine proteases |
| 07/21/2004 | EP1438313A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 07/21/2004 | EP1438311A2 A method of simultaneously treating sensory auditory gating deficit and associated psychosis in schizophrenia and bipolar disorder patients with mania |
| 07/21/2004 | EP1438310A1 Beta-carbolin derivatives as ptp-inhibitors |
| 07/21/2004 | EP1438309A1 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| 07/21/2004 | EP1438308A1 N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists |
| 07/21/2004 | EP1438307A2 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 07/21/2004 | EP1438304A1 Novel substituted 4-phenyl-4- 1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
| 07/21/2004 | EP1438302A1 New sulfonamide derivatives as d3-receptor agonists |
| 07/21/2004 | EP1438299A1 Bifunctional chelating agent for actinium |
| 07/21/2004 | EP1438298A1 Piperazine derivatives with ccr1 receptor antagonist activity |
| 07/21/2004 | EP1438297A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina |
| 07/21/2004 | EP1438296A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
| 07/21/2004 | EP1438295A2 Azole derivatives and pharmaceutical compositions containing them |
| 07/21/2004 | EP1438293A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 07/21/2004 | EP1438292A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 07/21/2004 | EP1438291A1 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same |
| 07/21/2004 | EP1438290A1 Cyclohept b!indole derivatives as spla2 inhibitors |
| 07/21/2004 | EP1438289A1 Indole derivatives as cox ii inhibitors |
| 07/21/2004 | EP1438288A1 Substituted thioacetamides |
| 07/21/2004 | EP1438285A1 Acetic acid derivatives |
| 07/21/2004 | EP1438283A1 Dicarboxylic acid derivatives, their preparation and therapeutic use |
| 07/21/2004 | EP1438281A2 Functionalized stilbene derivatives as improved vascular targeting agents |
| 07/21/2004 | EP1438104A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists |
| 07/21/2004 | EP1438074A2 Adjuvant compositions |
| 07/21/2004 | EP1438073A2 Polyoxyalkylenes conjugates as enzyme inhibitors |
| 07/21/2004 | EP1438071A1 Therapies for treating respiratory diseases |
| 07/21/2004 | EP1438069A1 Enzyme inhibitors for inactivating allergens |
| 07/21/2004 | EP1438063A1 Modulation of physiological processes and agents useful for same |
| 07/21/2004 | EP1438062A2 Methods and compositions for treating dermal lesions |
| 07/21/2004 | EP1438060A2 Prevention and treatment of restenosis by local administration of drug |
| 07/21/2004 | EP1438056A1 Drug for treating a fibrotic disease through rna interfence |
| 07/21/2004 | EP1438055A1 D-tagatose as an anti-biofilm agent |
| 07/21/2004 | EP1438054A1 Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| 07/21/2004 | EP1438053A1 Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same |
| 07/21/2004 | EP1438052A1 INHIBITORS OF HUMAN PHOSPHATIDYL−INOSITOL 3−KINASE DELTA |
| 07/21/2004 | EP1438051A1 An enantiomerically pure diarylmethylpiperazine and methods of using same |
| 07/21/2004 | EP1438050A2 Irinotecan for treatment of cancer |
| 07/21/2004 | EP1438049A2 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
| 07/21/2004 | EP1438048A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| 07/21/2004 | EP1438047A2 Compounds for reducing excessive intake of food |
| 07/21/2004 | EP1438046A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 07/21/2004 | EP1438045A1 Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake |
| 07/21/2004 | EP1438044A1 Bis-heteroaryl alkanes as therapeutic agents |
| 07/21/2004 | EP1438043A2 Method of reducing type 2 diabetes in high risk patients |
| 07/21/2004 | EP1438042A2 Polymaleimide compounds and their medical use |
| 07/21/2004 | EP1438041A2 Spermicides |
| 07/21/2004 | EP1438040A1 Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt |
| 07/21/2004 | EP1438039A2 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 07/21/2004 | EP1438038A1 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| 07/21/2004 | EP1438037A1 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue |
| 07/21/2004 | EP1438036A2 Use of sulfonamide derivatives as pharmaceuticals compounds |
| 07/21/2004 | EP1438035A2 Pharmaceutical compositions for the treatment of urinary disorders |
| 07/21/2004 | EP1438034A2 Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence |
| 07/21/2004 | EP1438031A1 Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
| 07/21/2004 | EP1438030A2 Modified release dosage forms |
| 07/21/2004 | EP1438028A1 Modified release dosage forms |
| 07/21/2004 | EP1438027A1 Methods of treatment using a gastric retained losartan dosage |
| 07/21/2004 | EP1438026A2 Taste masking spill-resistant formulation |
| 07/21/2004 | EP1438023A1 Novel process |
| 07/21/2004 | EP1438022A1 Drug release system for controlled therapy |
| 07/21/2004 | EP1438020A2 Topical compositions and methods for treating pain |
| 07/21/2004 | EP1438019A1 Kit for the preparation of a pharmaceutical composition |
| 07/21/2004 | EP1438018A1 Fondant-based pharmaceutical composition |
| 07/21/2004 | EP1438015A2 Cosmetic and dermopharmaceutical compositions for skin prone to acne |
| 07/21/2004 | EP1438014A2 Oil-in-water emulsion containing non-polar active principles |
| 07/21/2004 | EP1438001A2 Compositions and methods for inhibiting eccrine perspiration in humans |